HCPCS Code J9030: BCG Live Intravesical Instillation, 1 mg

## **J9030 documentation requirements** Thorough records are essential for medical necessity, safety, and clean claims. ### **Diagnosis and plan of care** Document non–muscle-invasive bladder cancer, risk category, and the BCG course (induction/maintenance). Clearly explain why BCG is selected. ### **Drug identification and lot details** Record BCG drug brand, strength, vial size, lot number, expiration, and doses prepared. ### **Dose, route, and units** State the exact milligrams instilled and J9030 units (1 mg = 1 unit), route as intravesical, and date/time of administration. ### **Procedure specifics** Describe catheter placement, dwell time, post-procedure instructions, and PPE/waste handling. Include anesthesia/analgesia if used. ### **Safety monitoring and consent** Note adverse effects, vitals, culture results if obtained, and provide informed consent discussion (e.g., infection risk and contraindications). ### **Prior therapies and outcomes** Summarize prior TURBT/chemotherapy, response to earlier BCG, and objective outcomes (recurrence/progression surveillance).

## **J9030 billing requirements** Follow these steps to support payment accuracy and reduce denials. ### **Units and per-dose accuracy** Report J9030 per 1 mg; match billed units to the milligrams instilled without rounding. ### **Modifiers and wastage** When using a single-dose vial, report JW for discarded amounts and JZ when no waste occurred, consistent with CMS waste reporting policy. ### **CPT pairing for the procedure** Pair the drug code with the appropriate procedural CPT for intravesical therapy (see “Other relevant codes”) and ensure documentation supports the service level. ### **NDC and claim narrative** Include NDC, lot/exp, and a concise description in the claim narrative (Box 19/electronic remarks) to meet payer billing requirements. ### **Coverage checks** Verify Medicare and commercial payer policies; some payers may crosswalk or publish a new code during shortages—incorporate payer instructions before submission.

## **J9030 applicable modifiers** Use modifiers per payer policy and clinical context: - JW - Drug amount discarded/not administered: Append on a separate line to bill documented wastage from a single-dose vial. - JZ - Zero drug wasted: Append when the entire vial contents were used with no discard. - TB - 340B acquisition (informational): Append when required to identify 340B purchases (does not change payment unless policy states). Always confirm payer-specific rules; CMS and MACs may update waste reporting instructions.

## **Other relevant codes** These codes frequently appear with J9030 in intravesical therapy workflows or related uro-oncology care: - 51720 – Intravesical instillation of anticarcinogenic agent (includes dwell/retention time documentation). - 51702 – Insertion of temporary indwelling bladder catheter (simple). - 51701 – Insertion of non-indwelling bladder catheter. - 90586 – BCG vaccine, percutaneous, for immunization (not for intravesical treatment of cancer). - 52234 / 52235 / 52240 – Cystourethroscopy with transurethral resection of bladder tumor (by size), used in diagnosis/management pathways around intravesical therapy.